ArticleLupus science & medicine2022
Response to therapy at 6 months predicts long-term renal outcome in lupus nephritis with poor kidney function.
Article in Lupus science & medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 3 citations in OpenAlex.
- Early renal response and baseline serum albumin in childhood proliferative lupus nephritis managed with a mycophenolate mofetil-first, response-guided strategy.Pediatric nephrology (Berlin, Germany) · 2026Article
- Refractory lupus nephritis: national multicenter study.Internal and emergency medicine · 2026Article
- Kidney Biopsy and Prognosis in Lupus Nephritis: Histological Predictors of Renal Outcome-A Narrative Review.Medicina (Kaunas, Lithuania) · 2026Review
- The Inverted Pyramid Approach: Early Combination Therapy With Voclosporin and Obinutuzumab in Active Lupus Nephritis.Cureus · 2026Article
- Rapid Reduction in Proteinuria With the Initiation of Voclosporin in Lupus Nephritis: A Single-Center Experience.Cureus · 2026Article
- NLRP3 inflammasomes pathway: a key target for Metformin.Inflammopharmacology · 2025Review
- The influence of genetic variants of IL-6 (-174 G/C) and INFγ (+ 874 A/T) and their impact on anemic Sudanese children with kidney failure.BMC research notes · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveIt is unclear whether aggressive treatment would benefit lupus nephritis (LN) with poor renal function, which has been excluded from most clinical trials. We aimed at demonstrating their clinicopathological features and prognosis.
methodsFrom August 2012 to December 2018, patients with active LN with poor renal function (estimated glomerular filtration rate (eGFR) between 15 and 59 mL/min/1.73 m
resultsA total of 107 patients were included. At 6 months, 18.7%, 38.3% and 43.0% of patients achieved CR, PR and no response (NR), respectively. During a median follow-up of 60 months, 40.2% ended up with reduced renal function (eGFR <60 mL/min/1.73 m
conclusionsIn patients with LN with poor renal function, no response at 6 months predicts a poor long-term renal outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.